Bristol-Myers Squibb to present at The Liver Meeting

Presentations include hepatitis B, hepatitis C, liver cancer studies

PRINCETON, N.J. — Bristol-Myers Squibb will present 22 study abstracts next month at the 62nd annual meeting of the American Association for the Study of Liver Diseases in San Francisco, the company said.

Key presentations set to take place at the meeting, called The Liver Meeting, include studies on the hepatitis B drug Baraclude (entecavir) and drugs under development for hepatitis C and liver cancer.

"Bristol-Myers Squibb is at the forefront of innovation in researching the treatment of liver diseases," Bristol-Myers Squibb SVP global development and medical affairs for research and development Brian Daniels said. "In hepatitis C, where there remains considerable unmet medical needs, our goal is to increase treatment options for patients by developing a portfolio of compounds with different mechanisms of action."

Interested in this topic? Sign up for our weekly Retail Health Provider e-newsletter.

Login or Register to post a comment.